Exercise Training, Recovery, Strength
Conditions
Keywords
ashwagandha, athlete, recovery, performance, cortisol
Brief summary
This double-blind, randomised, placebo-controlled trial will examine the effects of 42-day root extract ashwagandha (KSM-66) supplementation on recovery and muscle strength in male and female rugby and water polo players. Participants will receive either 600 mg of ashwagandha or a placebo daily. Outcomes include hormonal stress markers, perceived exertion, wellness, muscle soreness and strength and performance metrics (grip strength, jump tests, 1RM lifts, Bronco test).
Detailed description
This double-blind, randomised, placebo-controlled trial aims to investigate the effects of ashwagandha (ASH) supplementation on recovery and muscle strength in male and female rugby and water polo players. Participants will supplement either KSM-66 ashwagandha (600 mg, standardised to 5% withanolides) or a placebo once daily for 42 days. The study will evaluate outcomes related to hormonal stress markers, perceived exertion, wellness, muscle soreness, and physical performance. Primary biomarkers include cortisol, DHEA-S, testosterone, melatonin, alpha-amylase, and cortisone, assessed through saliva samples. Subjective measures will include the Borg Rate of Perceived Exertion Scale and the Hooper Index for sleep quality, stress, fatigue, and delayed onset muscle soreness (DOMS). Physical performance will be assessed using grip strength (CAMRY dynamometer), vertical jump tests (countermovement jump, squat jump), broad jump, 1-repetition maximum (1RM) tests for deadlift, bench press, and pull-up, as well as the Bronco test. Supplement satisfaction will be evaluated via questionnaire. Participants' dietary intake will be recorded using a self-tracking method (Snap-N-Send) and analysed using Nutritics software; food diaries will serve as covariates in the final analysis. The study will be conducted in partnership with CN Poble Nou, a professional sports club in Barcelona, Spain. Ashwagandha use is increasingly common among athletes despite limited evidence on appropriate dosing and performance outcomes. This study will contribute to scientific understanding of its potential short-term benefits, particularly in high-contact sports where managing cortisol and recovery is critical. All participants will provide informed consent, and ethical considerations focus on safety, data privacy, and the right to withdraw from the study at any time.
Interventions
Root extract ashwagandha, KSM-66
Organic chickpea flour
Sponsors
Study design
Eligibility
Inclusion criteria
* Above the age of 18 * Healthy and free of disease * Assigned as an athlete at CN Poble Nou sports academy
Exclusion criteria
* Allergies to nightshades such as tomato, aubergine, potatoes and peppers * Active supplementation with other ergogenic aids (to not interfere with existing treatment) * Medication or contraceptives (to not interfere with existing treatment) * Liver conditions (to not interfere with existing treatment) * Thyroid conditions (to not interfere with existing treatment) * Diabetes or certain autoimmune conditions (to not interfere with existing treatment) * Active pregnancy (to not interfere with existing treatment) * No signing of the consent form
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cortisol | Baseline and final measurement at 6 weeks | Salivary cortisol |
| Hand grip | Baseline and final measurement at 6 weeks | Hand grip strength in kilograms, CAMRY dynanometer |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| DHEA-s | Baseline and final measurement at 6 weeks | Salivary DHEA-s |
| Alpha-amylase | Baseline and final measurement at 6 weeks | Salivary alpha-amylase |
| Testosterone | Baseline and final measurement at 6 weeks | Salivary testosterone |
| Bronco test | Baseline and final measurement at 6 weeks | Aerobic fitness test in minutes and seconds |
| Cortisone | Baseline and final measurement at 6 weeks | Salivary cortisone |
| Melatonin | Baseline and final measurement at 6 weeks | Salivary melatonin |
Countries
Spain